• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坎帕拉穆拉戈医院镰状细胞病患者的腺样体扁桃体肥大与血管闭塞性危象发生频率:一项非匹配病例对照研究

Adenotonsillar hypertrophy and frequency of vaso-occlusive crisis in patients with sickle cell disease at Mulago hospital, Kampala: An unmatched case-control study.

作者信息

Muhereza Brian, Ndoleriire Christopher, Ndeezi Grace, Matsiko Sedrack, Nabawanga Stella, Esther Nakasagga

机构信息

Department of Ear, Nose, and Throat, School of Medicine, College of Health Sciences, Makerere University, Uganda.

Department of Ear, Nose, and Throat, School of Medicine, College of Health Sciences, Makerere University, Uganda.

出版信息

Pediatr Neonatol. 2025 Jul 9. doi: 10.1016/j.pedneo.2025.01.017.

DOI:10.1016/j.pedneo.2025.01.017
PMID:40683787
Abstract

OBJECTIVES

This unmatched case-control study compared the mean frequency of vaso-occlusive crisis in sickle cell disease patients aged 2-17 years with adenotonsillar hypertrophy (ATH) and those without at Mulago Hospital, Kampala, Central Uganda.

METHODS

From September to December 2022, sickle cell disease patients aged 2-17 years were examined using headlight illumination, a tongue depressor, and a post-nasal x-ray to diagnose adenotonsillar hypertrophy. Social-demographic characteristics, medical history, and physical examination findings were recorded using a data collection form. Patients who had bone pain requiring hospitalization in the previous 6 months were regarded as having a vaso-occlusive crisis. Those with a diagnosis of ATH (cases) were compared to those without (controls). Data were collected and managed using an open data kit (ODK) and analysed using STATA version 16. A T-test was used to compare the mean frequency of vaso-occlusive crisis between Cases and Controls.

RESULTS

There was a significant difference in the mean frequency of painful vaso-occlusive crises suffered in the previous 6 months between cases and controls (p value = 0.018). Age of 15-18 years [OR(CI):1.56, AOR:2.59; p = 0.047], females [OR(CI):1.68, AOR: 2.35; p = 0.003], snoring [OR(CI):12.01, AOR:8.4; p < 0.0001], and children who predominately breathe through the mouth [OR(CI):12.92, AOR:5.14; p = 0.001] were all associated with increased odds of adenotonsillar hypertrophy. Among disease-modifying factors, patients who were taking hydroxyurea [OR(CI): 2.16, AOR: 2.33; p = 0.027] had higher odds of adenotonsillar hypertrophy.

CONCLUSION

Children with sickle cell disease and adenotonsillar hypertrophy are at risk of suffering more pain vaso-occlusive crises compared to their healthy counterparts. The presence of obstructive adenotonsillar hypertrophy in children with sickle cell disease increases sickle cell morbidity, so more attention to these children through routine screening, diagnosis, and timely therapeutic intervention could reduce the morbidity.

摘要

目的

本非匹配病例对照研究比较了乌干达中部坎帕拉穆拉戈医院2至17岁患有腺样体扁桃体肥大(ATH)的镰状细胞病患者与未患该病患者血管闭塞性危机的平均发生频率。

方法

2022年9月至12月,对2至17岁的镰状细胞病患者使用头灯照明、压舌板和鼻后X光检查来诊断腺样体扁桃体肥大。使用数据收集表记录社会人口学特征、病史和体格检查结果。过去6个月内有需要住院治疗的骨痛患者被视为发生了血管闭塞性危机。将诊断为ATH的患者(病例)与未患该病的患者(对照)进行比较。使用开放数据工具包(ODK)收集和管理数据,并使用STATA 16版本进行分析。采用T检验比较病例组和对照组血管闭塞性危机的平均发生频率。

结果

病例组和对照组在过去6个月内发生疼痛性血管闭塞性危机的平均频率存在显著差异(p值 = 0.018)。15至18岁[比值比(置信区间):1.56,调整后比值比:2.59;p = 0.047]、女性[比值比(置信区间):1.68,调整后比值比:2.35;p = 0.003]、打鼾[比值比(置信区间):12.01,调整后比值比:8.4;p < 0.0001]以及主要通过口腔呼吸的儿童[比值比(置信区间):12.92,调整后比值比:5.14;p = 0.001]均与腺样体扁桃体肥大的几率增加相关。在疾病修饰因素中,服用羟基脲的患者[比值比(置信区间):2.16,调整后比值比:2.33;p = 0.027]患腺样体扁桃体肥大的几率更高。

结论

与健康儿童相比,患有镰状细胞病和腺样体扁桃体肥大的儿童发生更多疼痛性血管闭塞性危机的风险更高。镰状细胞病患儿存在阻塞性腺样体扁桃体肥大增加了镰状细胞病的发病率,因此通过常规筛查、诊断和及时的治疗干预对这些儿童给予更多关注可以降低发病率。

相似文献

1
Adenotonsillar hypertrophy and frequency of vaso-occlusive crisis in patients with sickle cell disease at Mulago hospital, Kampala: An unmatched case-control study.坎帕拉穆拉戈医院镰状细胞病患者的腺样体扁桃体肥大与血管闭塞性危象发生频率:一项非匹配病例对照研究
Pediatr Neonatol. 2025 Jul 9. doi: 10.1016/j.pedneo.2025.01.017.
2
Magnesium for treating sickle cell disease.镁用于治疗镰状细胞病。
Cochrane Database Syst Rev. 2017 Apr 14;4(4):CD011358. doi: 10.1002/14651858.CD011358.pub2.
3
Preoperative blood transfusions for sickle cell disease.镰状细胞病的术前输血
Cochrane Database Syst Rev. 2016 Apr 6;4(4):CD003149. doi: 10.1002/14651858.CD003149.pub3.
4
Inhaled nitric oxide for treating pain crises in people with sickle cell disease.吸入一氧化氮治疗镰状细胞病患者的疼痛危象。
Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD011808. doi: 10.1002/14651858.CD011808.pub3.
5
Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.低分子量肝素用于治疗镰状细胞病患者的血管闭塞性危象。
Cochrane Database Syst Rev. 2015 Dec 18;2015(12):CD010155. doi: 10.1002/14651858.CD010155.pub3.
6
Vitamin D supplementation for sickle cell disease.镰状细胞病的维生素D补充治疗
Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD010858. doi: 10.1002/14651858.CD010858.pub2.
7
Tonsillectomy or adenotonsillectomy versus non-surgical management for obstructive sleep-disordered breathing in children.扁桃体切除术或腺样体扁桃体切除术与非手术治疗对儿童阻塞性睡眠呼吸障碍的疗效比较
Cochrane Database Syst Rev. 2015 Oct 14;2015(10):CD011165. doi: 10.1002/14651858.CD011165.pub2.
8
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟脲)治疗镰状细胞病。
Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3.
9
Hospital Readmissions Among People With Sickle Cell Disease.镰状细胞病患者的医院再入院情况。
JAMA Netw Open. 2025 Jun 2;8(6):e2517974. doi: 10.1001/jamanetworkopen.2025.17974.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.